Adjuvant hyperthermia can improve treatment outcome for locally recurrent breast cancer (LRBC). Previously, we demonstrated that infection of human breast cancer cells with a recombinant adenovirus expressing b-galactosidase from the human hsp70b gene promoter (Ad.70b.bgal) results in 50-to 800-fold increases in reporter gene expression following heat treatment (30 minutes at 431C). Here, we describe a heat-directed suicide gene therapy strategy based on an adenoviral vector (Ad.70b.CDTK) in which expression of the dual prodrug-activating E. coli cytosine deaminase/herpes simplex virus thymidine kinase (CDTK) fusion gene is under the control of the hsp70b promoter. Treatment of T47D and MCF-7 breast cancer cells with mild hyperthermia (431C/30 minutes) and prodrugs (100 mg/ml 5-fluorocytosine and 10 mg/ml ganciclovir) following infection with Ad.70b.CDTK (10-100 PFU/ cell) resulted in 30-to 60-fold decreases in clonogenic survival relative to control cultures treated with heat or prodrugs alone. Clonogenic survival declined even further (up to 240-fold) following heat treatment at 41.51C for 120 minutes. A decreased clonogenic survival was accompanied by tumor cell apoptosis. These results demonstrate that this combined treatment strategy can be highly effective against heat-and radiation-resistant breast tumor cells and supports the continued development of heat-directed CDTK suicide gene therapy strategies for LRBC.
B
reast cancer is the second leading cause of cancerrelated death among women. 1 Early detection and advances in conventional treatment (surgery, radiation, and chemotherapy) have improved outcome. However, 10-15% of women treated for early breast cancer suffer a local recurrence (locally recurrent breast cancer, LRBC) within 10 years. 2 Local failure causes significant physical and psychosocial morbidity, 3 and the majority of these patients die of their disease within 5 years of recurrence. 4 Combined treatment of LRBC with radiation and hyperthermia (local tumor heating to a target temperature of 41-441C) can significantly improve response rates 3, 5 and is now a standard practice in some centers. 3 This treatment offers palliation for many patients (complete response rate B70%), but most die of their disease after developing local morbidity. Further improvement of LRBC treatment remains an important goal.
We 6 and others [7] [8] [9] [10] [11] [12] have been working to harness hyperthermia as a modality to target therapeutic gene expression to tumor cells. Studies to date have demonstrated that hyperthermia shows significant promise as a way to achieve treatment-targeted, spatiotemporal control of gene expression in vitro 6, [8] [9] [10] [11] [12] [13] and in vivo. 6, [8] [9] [10] [11] [12] [13] LRBC is an excellent choice for the clinical application of heat-directed cancer gene therapy in that it is prevalent, responds to hyperthermia and is relatively uncomplicated in terms of treatment planning for heat dosimetry. It is also amenable to gene therapy because its superficial and localized nature renders it easily accessible for vector administration.
In this study we test the hypothesis that heat-directed suicide gene therapy can enhance thermosensitivity in LRBC. Given the relapse rate following thermoradiotherapy for LRBC and the fact that cells can be intrinsically resistant to heat, 14, 15 we studied breast cancer cell lines (MCF-7 and T47D) that were resistant to heat-induced cell death. Previous studies in our laboratory demonstrated a 50-to 800-fold increase in reporter gene expression following heat treatment (30 minutes at 431C) of a panel of human breast cancer cell lines infected with a recombinant adenovirus (Ad.70b.bgal) in which a b-galactosidase reporter gene was placed under the control of the wild-type hsp70b gene promoter. 6 For this study an adenoviral vector (Ad.70b.CDTK) was constructed in which the hsp70b promoter controls expression of the dual prodrug-activating E. coli cytosine deaminase/herpes simplex virus thymidine kinase (CDTK) fusion gene. The CDTK fusion protein has been shown previously to be highly cytotoxic in a variety of tumor cell types both in vitro and in vivo [16] [17] [18] when expressed in the presence of the prodrugs 5-fluorocytosine (5-FC) and ganciclovir (GCV). Importantly, this therapeutic strategy was shown to act synergistically with heat treatment in a human prostate cancer model. 7 Here we show for the first time that adenovirus-mediated, heatdirected expression of a CDTK fusion gene can significantly decrease the survival of thermoresistant human breast cancer cell lines treated with clinically relevant doses of prodrugs and heat.
Materials and methods

Cell lines and culture
MCF-7 (ATCC) and 293 cells (Microbix, Toronto, Ontario) were maintained in alpha minimal essential medium (aMEM) containing 10% v/v fetal bovine serum (FBS). T47D cells (ATCC) were cultured in RPMI 1640 media plus 10% FBS. All cell culture media were supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin. All culture reagents were purchased from Gibco BRL/Life Technologies (Burlington, Ontario, Canada) except FBS (Bio-Whittaker, Walkersville, MD). Cells were incubated at 371C in 5% CO 2 . For cell heating, flasks or dishes (Nunc, Rosilde, Denmark) of cells were sealed and immersed in a calibrated water bath (Grant Instruments, Cambridge, UK). The desired temperature was maintained at 70.051C for the stipulated time. Following heating, flasks were immediately returned to the 371C incubator.
Adenoviral vector construction
A schematic representation of Ad.70b.CDTK, a replication-defective recombinant adenovirus containing the CDTK fusion gene under the control of the hsp70b promoter, is shown in Figure 1 . This adenoviral vector was created by first subcloning a BamHI/HindIII fragment carrying the hsp70b promoter 6 into the pDE1-sp1A adenoviral shuttle vector (Microbix, Toronto, Ontario, Canada). The CDTK cDNA was excised from pCA14-CDglyTK (a kind gift from Dr S Feytag, Henry Ford HC, Detroit, MI) as a BamHI (partial digest)/BglII fragment and cloned downstream of the hsp70b promoter in pDE1sp1A to create pDE1sp1A.70b.CDTK. Cotransfection of pDE1sp1A.70b.CDTK and the adenoviral genomic plasmid pJM17 (Microbix, Toronto, Ontario) into 293 cells generated the replication-defective Ad.70b.CDTK adenovirus by homologous recombination. 19 Individual purified viral plaques were screened for the presence of hsp70b.CDTK sequences by PCR. Positive recombinant plaques were verified by Western blotting for recombinant CDTK protein expression following infection of tumor cells. Recombinant adenoviral stocks were prepared and titered using established methods. 19 
Clonogenic assays
MCF-7 or T47D cells were plated in 25 mm 2 flasks and 24 hours later were infected with Ad.hsp70b.CDTK at multiplicity of infections (MOIs) ranging from 1 to 100 PFU/cell. Cells were infected by overlaying 500 ml of serum free aMEM containing appropriate concentrations of recombinant adenovirus for 1 hour at 371C. Growth medium (4.5 ml) was added and cells were incubated for another 24 hours at 371C before heat treatment. Fresh growth medium with or without GCV (10 mg/ml) and 5-FC (100 mg/ml) was added to cells immediately following heat or control treatment. After a further 48-hour incubation, cells were trypsinized, counted, diluted in fresh medium, and seeded in 100 mm 2 dishes at a density of 2.5 Â 10 2 -1 Â 10 5 cells/dish. MCF-7 and T47D cells were incubated for 14 and 21 days, respectively, to allow for colony formation and then fixed and stained with methylene blue in 50% ethanol. The number of colonies that contained at least 50 cells were counted on triplicate dishes.
Western blot analysis of CDTK expression
Western blot analysis of CDTK fusion protein expression was performed using the 4C8 monoclonal antibody (kindly provided by Dr WC Summers, Yale University, New Haven, CT) essentially as previously described. Briefly, cell lysates were isolated from infected cells after heat or control treatment and protein concentrations determined using the Bio-Rad assay (Bio-Rad, Richmond, CA). Equal amounts of protein (10 mg) were fractionated on 10% SDS-PAGE gels and transferred to nitrocellulose membranes (Bio-Rad, Richmond, CA). Western blots were incubated with a 1:300 dilution of the 4C8 monoclonal antibody at 221C for 1 hour. Blots were then washed and incubated with a horseradish peroxidase-conjugated secondary goat anti-mouse antibody (1:250 dilution) (Amersham Life Science) at 221C for 1 hour. Reactive bands were visualized by enhanced chemiluminescence (DuPont NEN, Boston, MA) and autoradiography.
Acridine orange and ethidium bromide staining
Cells were stained with acridine orange and ethidium bromide as described previously. 20, 21 Briefly, cells were collected, washed, and resuspended in PBS containing acridine orange and ethidium bromide (4 mg/ml each). Stained cells were transferred to glass slides and visualized with a fluorescent microscope (Leica, Heebrug, Switzerland), images captured with a Leica DC digital camera, and processed using Leica IM1000 image analysis software (v 1.10). Apoptosis was quantified by counting cells displaying morphologic features of apoptosis (e.g. chromatin condensation, membrane blebbing, apoptotic bodies) in 3-500 cells per slide.
Results
Previous studies in our laboratory 6 and in others [7] [8] [9] [10] [11] [12] demonstrated that the human hsp70b promoter exhibits low levels of basal activity at 371C, but is induced as much as 800-fold in response to heat treatment of in vitro and in vivo tumor models. To examine whether this heat-directed gene targeting strategy can complement hyperthermia in breast cancer treatment, an E. coli cytosine deaminase/ herpes simplex virus 1 thymidine kinase (CDTK) fusion gene was cloned downstream of the hsp70b promoter in an adenoviral vector to generate Ad.70b.CDTK (Fig 1a) . The hsp70b.CDTK minigene replaces E1 sequences within the adenoviral genome and is positioned in the negative orientation relative to the direction of E1 transcription in order to minimize interference with the hsp70b promoter. Restriction endonuclease digestion of adenoviral genomic DNA, as well as PCR analysis using hsp70b/CDTKspecific primers, confirmed the integrity of the therapeutic minigene. Western blot analysis of tumor cell extracts infected with Ad.70b.CDTK demonstrated that the recombinant CDTK fusion protein is only expressed following heating to 431C for 30 minutes (Fig 1b) . No expression was evident in the absence of heat treatment. In order to test the utility of this heat-targeted prodrug conversion strategy in breast cancer cells, clonogenic survival assays were performed on MCF-7 and T47D cells infected with Ad.70b.CDTK (1-100 PFU/cell) and treated with heat alone (431C for 30 minutes) or with a combination of heat and prodrugs (GCV: 10 mg/ml; 5-FC: 100 mg/ml). Drug concentrations were chosen to reflect levels that can be achieved in human serum. 22, 23 As shown in Figure 2 , control experiments revealed that heat or prodrug treatment alone is not significantly cytotoxic to either cell line. In contrast, treatment with a combination of heat and prodrugs had significant effects on clonogenic survival. In MCF-7 cells, the surviving fraction of treated cells infected with Ad.70b.CDTK at MOIs of 1, 10, and 100 PFU/cell were reduced by 2.3-, 11-, and 57-fold, respectively, relative to untreated controls (Fig 2a) . As T47D cells are more Figure 2 Clonogenic survival of breast cancer cells following heatdirected suicide gene therapy. (a) MCF-7 cells were infected with Ad.70b.CDTK at an MOI of 0 (mock-infected), 1, 10 or 100 PFU/cell. After 24 hours cells were heated to either 371C (control) or 431C for 30 minutes and incubated in growth medium alone (control) or containing the prodrugs 5-FC (100 mg/ml) and GCV (10 mg/ml) for a further 48 hours. Cells were harvested, counted, diluted and plated in triplicate to determine clonogenic survival. Each point represents the mean7standard deviation of at least three independent experiments. (b) Clonogenic survival of T47D breast cancer cells infected with Ad.70b.CDTK at an MOI of 0 (mock), 3, or 10 PFU/cell followed by heat and prodrug treatment as described for MCF-7 cells in panel A. Adenoviral infection efficiencies in T47D cells are greater than for MCF-7 cells. An MOI of 3 and 10 PFU/cell represents an infective dose equivalent to 10 and 100 PFU/cell, respectively, in MCF-7 cells. (Fig  2b) . This represents a two-to three-fold greater resistance of T47D cells to this treatment regimen compared to MCF-7 cells. In contrast to heat or drug treatment alone, infection with increasing MOIs of Ad.70b.CDTK alone resulted in a modest, dose-dependent decrease in clonogenic survival in both cell lines. To ensure that the therapeutic effects observed in treated cells infected with Ad.70b.CDTK were specific to CDTK expression, a second set of control experiments were performed in which a heat-inducible adenovirus expressing the b-galactosidase reporter gene was substituted for Ad.70b.CDTK. No differences in clonogenic survival were observed in cells following single or combined treatments with prodrugs and heat (data not shown). Together these results demonstrate that heatdirected gene targeting of a CDTK fusion suicide gene can significantly augment the therapeutic effects of hyperthermia in thermoresistant breast cancer cells, even at heat doses that are relatively nontoxic.
Clinical trials of hyperthermia have demonstrated that tumor temperatures below 431C can be more readily achieved in the clinic. 5, 24 To determine if heat-directed CDTK gene therapy can be effective at a more clinically relevant temperature, MCF-7 and T47D cells were infected with Ad.70b.CDTK (MCF-7: 100 PFU/cell; T47D: 10 PFU/cell) and heated to 41.51C for times ranging from 30 to 120 minutes. The results are shown in Figure 3 . In the presence of 5-FC (100 mg/ml) and GCV (10 mg/ml), a three-to six-fold decrease in clonogenic survival was observed in MCF-7 and T47D cultures infected with Ad.70b.CDTK and heated to 41.51C for 30 minutes. This was significantly lower than the levels of cytotoxicity observed following heat treatment at 431C for 30 minutes (Fig 2) . However, MCF-7 cell cultures infected with Ad.70b.CDTK (100 PFU/cell) and heated to 41.51C for 60 or 120 minutes exhibited 44-and 130-fold decreases, respectively, in clonogenic survival relative to control cultures treated with heat alone (Fig 3a) . Similarly, 84-and 244-fold reductions in clonogenic survival were observed in T47D cultures infected with Ad.70b.CDTK (10 PFU/cell) and heated for 60 and 120 minutes at 41.51C (Fig 3b) . In both cell lines, heat treatment at 41.51C for 120 minutes produced therapeutic responses that were significantly greater than those observed at 431C for 30 minutes. Heat treatment alone (411C for up to 120 minutes) produced minimal levels of cytotoxicity in these cell lines, and no differences in clonogenic survival were observed in the presence or absence of prodrugs in cells infected with a control adenovirus expressing b-galactosidase. These results clearly demonstrate that heat-directed CDTK gene therapy can significantly enhance the therapeutic response of heat-resistant breast cancer cells to hyperthermia at clinically relevant temperatures.
In previous studies, we observed that adenovirusmediated gene transfer of HSVtk alone, followed by GCV treatment, produces variable therapeutic responses among different breast cancer cell lines that are mediated, at least in part, by the induction of apoptosis. 25 In those studies MCF-7 cells, and to a somewhat lesser extent T47D cells, were seen to be relatively resistant to this suicide gene therapy strategy. In view of the significant improvement in the therapeutic response of these breast cancer cell lines to heat-directed CDTK gene therapy, we next explored the contribution of apoptosis to this effect. For these experiments, experimental and control cultures Figure 3 Clonogenic survival of breast cancer cells following heat treatment at 41.51C. (a) MCF-7 cells were infected with Ad.70b.CDTK at an MOI of 100 PFU/cell and after 24 hours were heated to 41.51C for 0 (control), 30, 60, and 120 minutes. Cells were then incubated in growth medium alone (control) or containing the prodrugs 5-FC (100 mg/ml) and GCV (10 mg/ml) for a further 48 hours. Cells were harvested, counted, diluted and plated in triplicate to determine clonogenic survival. Each point represents the mean7standard deviation of at least three independent experiments. (b) Clonogenic survival of T47D breast cancer cells infected with Ad.70b.CDTK at an MOI of 10 PFU/cell and treated with heat and prodrugs as described for MCF-7 cells in panel A.
were prepared and treated in the same way as described for the clonogenic survival studies. Cells infected with Ad.70b.CDTK were stained with acridine orange and ethidium bromide 48 hours post-treatment with heat and prodrugs. The apoptotic fraction for each treatment condition was determined by counting the proportion of cells displaying morphological characteristics of apoptosis as described in Materials and methods.
Apoptotic fractions determined for MCF-7 and T47D cells treated at 431C for 30 minutes, or at 41.51C for 30-120 minutes, are shown in Figure 4 . Both cell lines consistently displayed baseline apoptotic fractions of Figure 4 Heat-directed CDTK gene therapy induces apoptosis of breast cancer cells. The proportion of tumor cells undergoing apoptosis (apoptotic fraction) was determined by staining with acridine orange and ethidium bromide and scoring 300-500 cells under each treatment condition for the presence of established morphological features of apoptosis (e.g. chromatin condensation, membrane blebbing, apoptotic bodies). (a) MCF-7 cells were infected with Ad.70b.CDTK at 100 PFU/cell, heated to 431C for 30 minutes and exposed to the prodrugs 5-FC (100 mg/ml) and GCV (10 mg/ml). Experimental conditions were designed to mirror the clonogenic survival experiments outlined in Figure 2a 3-4% in untreated and control-treated cultures. This was also observed in cells infected with a control adenovirus expressing b-galactosidase under the control of the hsp70b promoter and treated with heat (either 43 or 41.51C) and prodrugs (data not shown). In the 431C treatment group (Fig 4a, b) , a significant increase in apoptotic fraction was only observed in MCF-7 and T47D cultures infected with Ad.70b.CDTK and treated with both heat and prodrugs. At MOIs of 10 and 100 PFU/cell, the proportion of MCF-7 cells undergoing apoptosis increased to 12 and 19%, respectively. Similarly, apoptotic fractions increased to 8 and 15% in T47D cell cultures infected with equivalent doses of Ad.70b.CDTK (3 and 10 PFU/cell, respectively).
In the 41.51C treatment group (Fig 4c, d) , a 30-minute heat exposure resulted in only a marginal increase in the apoptotic fraction (6%) of MCF-7 and T47D cell cultures. However, the proportion of apoptotic cells increased steadily in cultures treated for 60 and 120 minutes. Apoptotic fractions of 11 and 17% were observed in MCF-7 cells infected with Ad.70b.CDTK (100 PFU/cell) and heated to 41.51C for 60 and 120 minutes, respectively. Apoptotic fractions increased to 13 and 17% in Ad.70b.CDTK (10 PFU/cell)-infected T47D cells following 60 and 120 minutes of heat treatment. Increased levels of apoptosis in each of these treatment groups are consistent with the decrease in clonogenic survival observed under these conditions. Evidence of an apoptotic response to heat-directed CDTK suicide gene therapy provides further support for the notion that this therapeutic strategy can provide a potent adjunct to hyperthermia in the treatment of heat-resistant breast cancer populations.
Discussion
There remains a desperate need to develop novel therapeutic strategies for LRBC that complement existing treatment modalities to minimize local recurrence and improve outcome. As an adjunct to radiotherapy, hyperthermia has been shown to significantly increase response rates and prolong relapse-free survival. 3, 24, 26 Hyperthermia can also enhance the cytotoxic effects of cisplatin and other chemotherapeutic agents. 27, 28 A second agent long known to be cytotoxic to breast tumors and to enhance the therapeutic effects of radiation is the pyrimidine analogue 5-fluorouracil (5-FU). 29 Suicide gene therapy strategies have been developed that employ the E. coli cytosine deaminase (CD) gene to convert the prodrug 5-FC to 5-FU in tumor cells, and Freytag et al. 16 have developed a dual prodrug-converting enzyme that combines the CD-5FU system with herpes simplex virus thymidine kinase (TK)-mediated conversion of the prodrug GCV. Gene transfer of this CDTK fusion gene was shown to enhance the radiation response of 9L glioma cells to a much greater extent than either prodrug-activating enzyme alone. In this study, we have constructed a recombinant adenoviral vector (Ad.70b.CDTK) in which the CDTK fusion gene is under the control of the hsp70b promoter. Previous studies in our laboratory 6 and in others [7] [8] [9] [10] [11] [12] have shown that adenoviral vectors incorporating the hsp70b promoter can provide high levels of therapeutic gene expression in tumor cells treated with mild hyperthermia. Here we examine the ability of heat-directed CDTK suicide gene therapy to complement hyperthermia in heat-resistant breast cancer cells. Treatment of T47D and MCF-7 breast cancer cells with heat (431C/30 minutes) and prodrugs (100 mg/ml 5-FC and 10 mg/ml GCV) following infection with Ad.70b.CDTK (10-100 PFU/cell) resulted in 30-to 60-fold decreases in clonogenic survival relative to control cultures. Clonogenic survival was decreased even further (up to 240-fold) following heat treatment at 41.51C for 120 minutes, and was associated with increased levels of apoptosis in both cell lines. These results clearly demonstrate that adenovirus-mediated heat-directed CDTK suicide gene therapy can significantly increase the therapeutic response of heat-resistant breast cancer cells treated with clinically relevant doses of heat and prodrugs. Furthermore, this therapeutic effect is mediated, at least in part, by an increase in the levels of tumor cell apoptosis.
Hyperthermia treatment alone has antitumor activity, but typically is used to sensitize tumor cells to other forms of treatment. 26 Like other conventional treatment modalities, the therapeutic effects of hyperthermia can be limited by intrinsic cellular resistance.
14, 15 The incidence of local failure in patients treated with combinations of hyperthermia and radiation 3, 5 emphasizes the need to better understand the molecular basis of heat resistance and to develop better therapeutics against this class of tumor cell. MCF-7 cells are resistant to both radiation and heat treatment, 30, 31 and carry several molecular defects associated with apoptotic signaling. For example, MCF-7 cells lack caspase 3, a critical mediator of apoptosis that lies downstream of the apoptosome complex.
30 T47D cells express mutant p53, and functional inactivation of the p53 tumor suppressor gene has been associated with increased resistance to hyperthermia. 32, 33 Although MCF-7 cells express wild-type p53, they also express unusually high levels of mdm2, which targets p53 for degradation. 34 Our observation of a strong cytotoxic response by T47D and MCF-7 cells to heat-directed CDTK gene therapy suggests that this therapeutic strategy can overcome defects in apoptotic signaling and can be highly effective against breast tumor cells that are resistant to heat and radiation treatment.
Clearly, much remains to be learned about the complex interplay of signaling events that converge to trigger apoptotic cell death in normal cells, how these molecular pathways are circumvented in tumor cells, and how they can be exploited to improve cancer treatment. Here we show that resistance to treatment can be overcome by combining heat-induced prodrug activation with hyperthermia. Mild hyperthermia and a relatively brief (48 hours) exposure to clinically relevant concentrations of 5-FC and GCV resulted in greater than 100-fold reductions in the clonogenic survival of heat-and radiation-resistant Heat-directed suicide gene therapy AM Brade et al human breast cancer cells. This is consistent with the decrease in clonogenic survival of PC-3 prostate cancer cells following heat-targeted gene expression of CDTK, 7, 35 and the beneficial effects of heat-targeted TK expression observed in a syngeneic mouse breast carcinoma model. 8 Together these results support the notion that, as an adjunct to radiotherapy for recurrent breast cancer, heat-directed CDTK suicide gene therapy may significantly improve treatment outcome.
A major obstacle to the successful application of heatdirected suicide gene therapy is the difficulty in achieving therapeutic levels of gene transfer to tumor cells in vivo.
No available vector system is capable of delivering a therapeutic gene to every cell in a tumor, underscoring the need to develop strategies that incorporate genes that produce strong bystander effects and complement existing therapeutic modalities. Recombinant adenoviral vectors have become prominent in cancer gene therapy applications because they can be produced at high titeres and infect both dividing and nondividing cells with high efficiency. Previous studies in our laboratory demonstrated that intratumoral injection of a replication-defective adenovirus carrying a heat-inducible b-galactosidase reporter gene produced patchy staining in heat-treated HeLa cell xenografts that corresponded to 10-15% of the total area of the tumor sections examined. 6 This result was consistent with staining patterns and transduction efficiencies achieved in other xenograft tumor models in our laboratory transduced with replication-defective adenoviral vectors expressing b-galactosidase from either a strong, constitutively active CMV promoter 36 or a targeted Epstein-Barr Virus-responsive promoter. 37 To address the issue of poor tumor transduction efficiency in vivo, conditionally replicative adenoviruses (CRA) are being developed that are designed to preferentially replicate in tumor cells by taking advantage of mutations in key regulatory genes (e.g. the E1b55k-deleted ONYX-015 adenovirus targeted to p53-deficient tumor cells 38 ) or by using tissue-specific (e.g. the prostatespecific antigen gene promoter 39 ) or ligand-inducible (e.g. rapamycin 40 ) promoter systems to drive the expression of E1 genes. These vectors would be expected to improve therapeutic outcome significantly since adenovirus replication is in itself oncolytic and would result in amplification of the therapeutic gene and further dissemination of the virus within the tumor. Conditionally replicating adenoviral vectors have already been shown to enhance significantly the therapeutic impact of cancer gene therapy strategies employing suicide genes, including the CDTK fusion gene used in this study. 41, 42 In addition, Lee et al 35 have described an E1b-attenuated conditionally replicating adenovirus in which CDTK gene expression is under the control of the HSP70b promoter. Infection of DU145 prostatic carcinoma and CX-1 colorectal carcinoma cells with this adenovirus resulted in greater than 1000-fold reductions in survival following treatment with drugs and mild hyperthermia in vitro. These observations raise the exciting prospect of integrating heat-directed CDTK suicide gene therapy with a conditionally replicating adenovirus targeted to breast cancer cells. 43, 44 In addition to significantly enhancing the impact of this therapeutic strategy in vivo, this would have the added benefit of improving patient safety by providing stringent control over CDTK suicide gene expression.
